Logo

Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder

Share this
Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder

Urovant's Gemtesa (vibegron) Receives the US FDA's Approval for Overactive Bladder

Shots:

  • The approval is based on P-III EMPOWUR and EMPOWUR long term extension study that involves assessing Gemtesa (75mg- qd) vs PBO in ~4000 patients with OAB for 12wks.
  • The study resulted in reductions in daily UUI- micturitions- and urgency episodes and an increase in the volume voided
  • Gemtesa is a small-molecule β3 adrenergic receptor agonist therapy that relaxes the detrusor bladder muscle so that the bladder can hold more urine- thus reducing symptoms of OAB. Gemtesa is the first oral branded FDA’s approved OAB medication since 2012- and it is the first product approval for Urovant Sciences

 ­ Ref: GLOBE NEWSWIRE | Image: Yahoo Finance

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions